{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:08:05Z","timestamp":1790798885827,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03901-z","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:36:11Z","timestamp":1739532971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-13 in immunohistochemistry: implications for Grover disease, morphea, and immune checkpoint inhibitor-induced bullous pemphigoid"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-6963","authenticated-orcid":false,"given":"Italo Francesco","family":"Aromolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Laura","family":"Boggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Romagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Maronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"16","key":"3901_CR1","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.3390\/ijms241612884","volume":"24","author":"E Roeb","year":"2023","unstructured":"Roeb E (2023) Interleukin-13 (IL-13)-A pleiotropic cytokine involved in Wound Healing and Fibrosis. Int J Mol Sci 24(16):12884 Published 2023 Aug 17. https:\/\/doi.org\/10.3390\/ijms241612884","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3901_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T (2020) Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954","journal-title":"Allergy"},{"issue":"5","key":"3901_CR3","doi-asserted-by":"publisher","first-page":"e15429","DOI":"10.1111\/dth.15429","volume":"35","author":"F Barei","year":"2022","unstructured":"Barei F, Torretta S, Morini N, Ferrucci S (2022) A case of Grover disease treated with Dupilumab: just serendipity or a future perspective? Dermatol Ther 35(5):e15429. https:\/\/doi.org\/10.1111\/dth.15429","journal-title":"Dermatol Ther"},{"key":"3901_CR4","doi-asserted-by":"publisher","first-page":"824110","DOI":"10.3389\/fimmu.2022.824110","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Mao X, Liu Y, Yang Y, Jin H, Li L (2022) IL-13 genetic susceptibility to Bullous Pemphigoid: a potential target for treatment and a prognostic marker. Front Immunol 13:824110. https:\/\/doi.org\/10.3389\/fimmu.2022.824110. Published 2022 Jan 24","journal-title":"Front Immunol"},{"issue":"2","key":"3901_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jid.2020.05.108","volume":"141","author":"E Miranda","year":"2021","unstructured":"Miranda E, Roberts J, Novick S et al (2021) Immunohistochemical characterization of the IL-13:IL-4 receptor \u03b1 Axis in the skin of adult patients with moderate to severe atopic dermatitis and healthy controls. J Invest Dermatol 141(2):440\u2013443e4. https:\/\/doi.org\/10.1016\/j.jid.2020.05.108","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3901_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000071783","volume":"207","author":"M Hasegawa","year":"2003","unstructured":"Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K (2003) Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 207(2):141\u2013147. https:\/\/doi.org\/10.1159\/000071783","journal-title":"Dermatology"},{"key":"3901_CR7","unstructured":"Randomized A Placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of Subcutaneous Dupilumab in Localized Scleroderma. ClinicalTrials.gov Identifier: NCT04200755. 2024, Ongoing."},{"issue":"3","key":"3901_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/pde.15200","volume":"40","author":"S Wang","year":"2023","unstructured":"Wang S, Berry CT, Treat JR, Jen M (2023) Morphea after initiation of dupilumab in two pediatric atopic dermatitis patients. Pediatr Dermatol 40(3):540\u2013543. https:\/\/doi.org\/10.1111\/pde.15200","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"3901_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N et al (2019) Atopic dermatitis is an IL-13-Dominant disease with Greater Molecular Heterogeneity compared to Psoriasis. J Invest Dermatol 139(7):1480\u20131489. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018Epub 2019 Jan 11. PMID: 30641038; PMCID: PMC6711380","journal-title":"J Invest Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03901-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T23:07:38Z","timestamp":1739574458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03901-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03901-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), with the Helsinki Declaration of 1975, as revised in 2000, and with the Taipei Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all the patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}